Goal · 37 compounds
Weight loss
24 of 37 compounds people take for weight loss have been through controlled trials in people
6 approved drugs · 18 controlled trials · 3 human pilots · 10 animal only · 0 no data · each counted by its own meter
FDA Approved 8
- Weight loss · Weekly shotSemaglutideGLP-1The weekly shot the FDA approved as Ozempic and Wegovy. Weight loss in its main trial: 14.9%, on average.Approved drugFDA approvedChecked Oct 18
- Weight loss · Weekly shotTirzepatideGLP-1Zepbound: the weekly shot that beat semaglutide head-to-head. Main trial: 20.9% weight loss at 72 weeks.Approved drugFDA approvedChecked Oct 18
- Weight loss · Daily shotLiraglutideGLP-1The daily shot before Ozempic, approved for teenagers from 12. Its main trial: 8% weight loss at 56 weeks.Approved drugFDA approvedChecked Oct 18
- Weight loss · PillOrforglipronGLP-1Foundayo: a daily weight-loss pill with no fasting rules. Phase 3: 11.2% weight loss at 72 weeks.Approved drugFDA approvedChecked Oct 18
- Weight loss · Daily shotSetmelanotideMelanocortinFor rare genetic obesity, not everyday weight loss. Phase 3: 8 of 10 patients lost at least 10% in a year.Approved drugFDA approvedChecked Oct 13
- Weight loss · Weekly shotDulaglutideGLP-1Trulicity: a weekly diabetes shot, not a weight-loss drug. The AWARD trials: 2–5 kg lost.Controlled trialsFDA approvedfor another useChecked Oct 18
- Weight loss · Daily shotExenatideGLP-1Byetta, the diabetes shot copied from Gila monster venom. Obese, no diabetes: 3.3% of weight beyond placebo.Controlled trialsFDA approvedfor another useChecked Oct 17
- Weight loss · Daily shotPramlintideAmylinApproved in 2005 for diabetics on insulin: three shots a day, boxed warning. Not a weight-loss drug.Controlled trialsFDA approvedfor another useChecked Oct 18
Gray Market 27
- Weight loss · Weekly shotRetatrutideGLP-1Lilly's triple-hormone shot, unapproved; gray-market copies sell anyway. Phase 3: 25.0% loss at 80 weeks.Controlled trialsGray marketChecked Oct 12
- Weight loss · Weekly shotCagrilintideAmylinThe other half of Novo's CagriSema combo. Alone it's gray-market; paired, 20.4% weight loss at 68 weeks.Controlled trialsGray marketChecked Oct 18
- Weight loss · Daily shotAOD-9604GH fragmentSold as growth hormone's fat-burning fragment. Its biggest trial, 502 people over 24 weeks, missed its goal.Controlled trialsGray marketChecked Oct 18
- Weight loss · Weekly shotMazdutideGLP-1Prescribed in China since 2025; not approved in the US. Main trial: 12.6% weight loss at 32 weeks.Controlled trialsGray marketChecked Oct 12
- Weight loss · Weekly shotSurvodutideGLP-1Boehringer's two-in-one weight-loss shot, in Phase 3. Phase 2 beat placebo by up to 12 points of body weight.Controlled trialsGray marketChecked Oct 18
- Weight loss · Weekly shotPetrelintideAmylinPitched as the weight-loss shot you can stay on. Phase 2: up to 9.8% at 28 weeks against 1.7% on placebo.Controlled trialsGray marketChecked Oct 18
- Weight loss · Weekly shotEloralintideAmylinLilly's next weight-loss shot, in trials only. Phase 2: 20% weight loss at 48 weeks in 263 adults.Controlled trialsGray marketChecked Oct 13
- Weight loss · Weekly shotAmycretinAmylinNovo's next weight-loss shot and pill, trials only. Every published result: Novo-funded trials, 759 people.Controlled trialsGray marketChecked Oct 18
- Weight loss · IV dripBimagrumabMyostatin blockerPitched as fat loss that keeps muscle. Alone, it took off less weight than semaglutide in a 507-adult trial.Controlled trialsGray marketChecked Oct 5
- Weight loss · Weekly shotCagriSemaAmylinNovo's two-drug shot built to beat Zepbound. 20.4% weight loss in Phase 3; the FDA hasn't ruled yet.Controlled trialsGray marketChecked Oct 18
- Weight loss · Weekly shotEcnoglutideGLP-1China's weekly weight-loss shot, billed as beating semaglutide. The proof: a conference poster at week 20.Controlled trialsGray marketChecked Oct 18
- Weight loss · Monthly shotMariTideGLP-1Amgen's bid for a once-a-month obesity shot. In print so far: one efficacy trial, 592 people, Amgen-funded.Controlled trialsGray marketChecked Oct 18
- Weight loss · Weekly shotPemvidutideGLP-1Altimmune's two-in-one weight-loss shot, in trials only. Phase 2: 15.6% loss at 48 weeks in 391 adults.Controlled trialsGray marketChecked Oct 11
- Weight loss · PillTesofensineSmall moleculeBack on the gray market since the weight-loss-shot shortages. Phase 2: 9.2% loss in 24 weeks; no Phase 3.Controlled trialsGray marketChecked Oct 18
- Weight loss · Weekly shotVK2735GLP-1Viking's rival to Mounjaro, in trials only. Phase 2: 14.7% weight loss in 13 weeks at the top dose.Controlled trialsGray marketChecked Oct 18
- Weight loss · PillCardarineSmall moleculeTaken as an exercise pill for fat loss. Its maker quit after 2-year rodent tests found tumors at every dose.Human pilotsGray marketTumors in rats and mice at every doseChecked Oct 12
- Weight loss · Weekly shotCT-388GLP-1Roche's weekly weight-loss shot, still in trials. Phase 2 poster, top dose: 18.3% beyond placebo at 48 weeks.Human pilotsGray marketChecked Oct 5
- Weight loss · Weekly shotGlumitideGIPLilly's trial-only shot, built from one half of Zepbound. Data: two Phase 1 studies, four weeks of dosing.Human pilotsGray marketChecked Oct 18
- Weight loss · Pill5-Amino-1MQSmall moleculeSold as a fat-loss pill for a stubborn metabolism. Every fat-loss result so far: obese mice, from one lab.Animal onlyGray marketChecked Oct 11
- Weight loss · Daily shotAdipotideCell-killing peptidePitched as a way to starve fat cells of blood. Obese monkeys lost 11% of their fat; their kidneys objected.Animal onlyGray marketKidney injury in monkeysChecked Oct 18
- Weight lossAICARSmall moleculeSold as exercise in a pill. The 2008 mice ran 44% farther; no human trial has matched it.Animal onlyGray marketChecked Oct 18
- Weight lossBAM15MitochondrialA research chemical that makes mitochondria waste fuel. In mice it stopped fat gain; human trials: zero.Animal onlyGray marketChecked Oct 12
- Weight loss · PillGW-0742Small moleculeA PPAR-delta agonist pitched as exercise in a pill. The evidence: mouse muscle papers; human trials: zero.Animal onlyGray marketChecked Oct 18
- Weight loss · Daily shotHGH Fragment 176-191GH fragmentSold as 'HGH frag' for fat loss. Human trials of this exact fragment: zero; its cousin AOD-9604 failed.Animal onlyGray marketChecked Oct 18
- Weight lossNesfatin-1NeuropeptideStudied since 2006 as an appetite brake. It has never been given to a person in a trial.Animal onlyGray marketChecked Oct 18
- Weight loss · PillSLU-PP-332Small moleculeA pill pitched as a workout substitute. The evidence: one 2023 mouse paper where mice ran 70% farther.Animal onlyGray marketChecked Oct 18
- Weight loss · PillSR9009Small moleculeSold online as exercise in a pill. The fat loss came from mice injected for 30 days; no human trial.Animal onlyGray marketCase report: liver failure, transplantChecked Oct 12
Also taken for this 2
- Muscle & strength · Daily shotTesamorelinGH secretagogueApproved for HIV-related belly fat; clinics use it off-label. Its 412-patient trial cut belly fat 15–18%.Approved drugFDA approvedChecked Oct 18
- Longevity · Weekly shotMOTS-cMitochondrialA peptide from mitochondrial DNA, pitched as exercise in a bottle. Human trials of it injected: zero.Animal onlyGray marketChecked Oct 18
- Legal today
- 9 FDA approved · 0 Compounded Rx · 28 Gray market
- What people actually run
- None of the seven named stacks